ADAG trades 27.2% below Wall Street's consensus target of $5.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ADAG achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Adagene Inc. (ADAG) has a Wall Street consensus price target of $5.00, based on estimates from 5 covering analysts. With the stock currently trading at $3.93, this represents a potential upside of +27.2%. The company has a market capitalization of $148M.
Analyst price targets range from a low of $5.00 to a high of $5.00, representing a 0% spread in expectations. The median target of $5.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ADAG trades at a trailing P/E of -8.5x. Analysts expect EPS to grow +64.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ZLABZai Lab Limited | $2.1B | $19.35 | $35.00 | +80.9% | Buy | — | 11 |
BCABBioAtla, Inc. | $5M | $4.08 | $250.00 | +6027.5% | Buy | — | 9 |
IMVTImmunovant, Inc. | $8.2B | $40.09 | $45.00 | +12.2% | Buy | — | 23 |
XNCRXencor, Inc. | $1.1B | $15.67 | $35.30 | +125.3% | Buy | — | 27 |
MGTXMeiraGTx Holdings plc | $1.4B | $14.66 | $25.00 | +70.5% | Buy | — | 6 |
RCUSArcus Biosciences, Inc. | $3.0B | $30.25 | $31.00 | +2.5% | Buy | — | 18 |
AGENAgenus Inc. | $146M | $3.50 | $7.33 | +109.4% | Buy | 4.5x | 11 |
NKTRNektar Therapeutics | $1.5B | $74.90 | $149.60 | +99.7% | Buy | — | 33 |
MRUSMerus N.V. | $6.8B | $90.00 | $88.69 | -1.5% | Hold | — | 22 |
REGNRegeneron Pharmaceuticals, Inc. | $70.3B | $676.23 | $836.00 | +23.6% | Buy | 14.6x | 48 |
Quick answers to the most common questions about buying ADAG stock.
The consensus Wall Street price target for ADAG is $5, representing 27.2% upside from the current price of $3.93. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ADAG has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $5 implies 27.2% upside from current levels.
ADAG's current price is $3.93 with a consensus target of $5 (27.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $5 for ADAG, while the most conservative target is $5. The consensus of $5 represents the median expectation. These targets typically reflect 12-month expectations.
ADAG is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ADAG stock forecast based on 5 Wall Street analysts shows a consensus price target of $5, with estimates ranging from $5 (bear case) to $5 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on ADAG, with a "Buy" consensus rating and $5 price target (27.2% upside). 5 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ADAG analyst price targets range from $5 to $5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.